leadf
logo-loader
viewAkers Biosciences, Inc.

Akers Biosciences chairman says China deal a ‘game changer’

Ray Akers, the co-founder and executive chairman of Akers Biosciences (LON:AKR, NASDAQ:AKER), calls the US$1mln order from China for its Heparin allergy tests a ‘game changer’ for the group.

Quick facts: Akers Biosciences, Inc.

Price: 14.21 USD

NASDAQ:AKR
Market: NASDAQ
Market Cap: $1.24 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Swift Media CEO says big opportunities in aged care will drive its future growth

Swift Media Ltd's (ASX:SW1) chief executive Pippa Leary tells Proactive's Andrew Scott they're a specialist technology firm supplying entertainment and communication systems that connect and engage isolated communities. ''We do a lot of work with residential aged care but more recently we've...

12 hours, 26 minutes ago

2 min read